Topic

Mike Hollan is an assistant managing editor for 

 and can be reached at mhollan@mjhlifesciences.com.

Articles

Accenture’s global life sciences technology lead discusses how the life sciences industry has embraced artificial intelligence.

Embracing AI: Q&A with Shalu Chadha

Webcasts

Webinar Date/Time: Thu, Oct 12, 2023 2:00 PM EDT

Driving Patient-First Affordability in Seconds, Not Days: Accelerating Time to Therapy

Webinar Date/Time: Tue, Oct 31, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST

Advancing Drug Discovery and Treatment Options With Patients and Citizen Science

Webinar Date/Time: Tue, Oct 17, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST

The Open, Closed, and Exploding World of Research Data

Webinar Date/Time: Tue, Sep 26, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST


Accelerating precision oncology with artificial intelligence

Webinar Date/Time: Tuesday, September 19th, 2023 at 8am PDT | 11am EDT | 4pm BST

Trends in Commercial Forecasting: Insights from IQVIA’s Annual Survey

Stacy Hartung is the vice president of marketing, technology, and data solutions at Syneos Health.

Suma Ramadas is an executive vice president and global head of medical affairs at Syneos Health.

How pharma medical affairs and commercial teams are synchronizing their capabilities to boost omnichannel marketing strategies and better understand customer engagement needs.

Bridging the Divide: Medical's Omnichannel Momentum

The application of artificial intelligence is steadily finding a home in the pharma industry, but these tools may have unprecedented potential in a more nascent niche along the life sciences continuum: drug development. 

AI and Drug 'Re-Innovation'

AI Impact on HCPs

Taylor Stucky is an associate research director at CBRE, a commercial real estate services company. She specializes in research about the life sciences sector.

Artificial intelligence may find a home in clinical trials and manufacturing in the coming years, but privacy, cyber security, and determining who owns the intellectual properties could pose challenges. 

Technology